|
nasdaq:psti
|
226821
|
Apr 21st, 2024 12:00AM
|
Pluri
|
13K
|
183.00
|
Open
|
|
Apr 20th, 2024 11:59PM
|
Apr 20th, 2024 11:59PM
|
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.
|
Open
|
Cell Therapy, Biotechnology, and Regenerative Medicine
|
Open
|
MATAM Park, Bldg #5
|
Haifa
|
|
IL
|
31905
|
|
Pluristem Therapeutics
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:psti
|
226821
|
Apr 20th, 2024 12:00AM
|
Pluri
|
13K
|
183.00
|
Open
|
|
Apr 19th, 2024 11:56PM
|
Apr 20th, 2024 05:31PM
|
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.
|
Open
|
Cell Therapy, Biotechnology, and Regenerative Medicine
|
Open
|
MATAM Park, Bldg #5
|
Haifa
|
|
IL
|
31905
|
|
Pluristem Therapeutics
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:psti
|
226821
|
Apr 19th, 2024 12:00AM
|
Pluri
|
13K
|
182.00
|
Open
|
|
Apr 19th, 2024 12:03AM
|
Apr 19th, 2024 12:03AM
|
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.
|
Open
|
Cell Therapy, Biotechnology, and Regenerative Medicine
|
Open
|
MATAM Park, Bldg #5
|
Haifa
|
|
IL
|
31905
|
|
Pluristem Therapeutics
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:psti
|
226821
|
Apr 18th, 2024 12:00AM
|
Pluri
|
13K
|
182.00
|
Open
|
|
Apr 18th, 2024 12:26AM
|
Apr 18th, 2024 06:51PM
|
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.
|
Open
|
Cell Therapy, Biotechnology, and Regenerative Medicine
|
Open
|
MATAM Park, Bldg #5
|
Haifa
|
|
IL
|
31905
|
|
Pluristem Therapeutics
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:psti
|
226821
|
Apr 17th, 2024 12:00AM
|
Pluri
|
13K
|
182.00
|
Open
|
|
Apr 16th, 2024 11:54PM
|
Apr 17th, 2024 03:17PM
|
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.
|
Open
|
Cell Therapy, Biotechnology, and Regenerative Medicine
|
Open
|
MATAM Park, Bldg #5
|
Haifa
|
|
IL
|
31905
|
|
Pluristem Therapeutics
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:psti
|
226821
|
Apr 16th, 2024 12:00AM
|
Pluri
|
13K
|
182.00
|
Open
|
|
Apr 15th, 2024 11:50PM
|
Apr 16th, 2024 11:33AM
|
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.
|
Open
|
Cell Therapy, Biotechnology, and Regenerative Medicine
|
Open
|
MATAM Park, Bldg #5
|
Haifa
|
|
IL
|
31905
|
|
Pluristem Therapeutics
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:psti
|
226821
|
Apr 15th, 2024 12:00AM
|
Pluri
|
13K
|
182.00
|
Open
|
|
Apr 14th, 2024 11:45PM
|
Apr 15th, 2024 05:15PM
|
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.
|
Open
|
Cell Therapy, Biotechnology, and Regenerative Medicine
|
Open
|
MATAM Park, Bldg #5
|
Haifa
|
|
IL
|
31905
|
|
Pluristem Therapeutics
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:psti
|
226821
|
Apr 14th, 2024 12:00AM
|
Pluri
|
13K
|
181.00
|
Open
|
|
Apr 13th, 2024 11:34PM
|
Apr 13th, 2024 11:34PM
|
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.
|
Open
|
Cell Therapy, Biotechnology, and Regenerative Medicine
|
Open
|
MATAM Park, Bldg #5
|
Haifa
|
|
IL
|
31905
|
|
Pluristem Therapeutics
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:psti
|
226821
|
Apr 13th, 2024 12:00AM
|
Pluri
|
13K
|
181.00
|
Open
|
|
Apr 12th, 2024 11:26PM
|
Apr 13th, 2024 12:00PM
|
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.
|
Open
|
Cell Therapy, Biotechnology, and Regenerative Medicine
|
Open
|
MATAM Park, Bldg #5
|
Haifa
|
|
IL
|
31905
|
|
Pluristem Therapeutics
|
Health Care
|
Health Care Equipment & Services
|
|
nasdaq:psti
|
226821
|
Apr 12th, 2024 12:00AM
|
Pluri
|
13K
|
181.00
|
Open
|
|
Apr 11th, 2024 11:32PM
|
Apr 12th, 2024 08:55AM
|
Pluri is pushing the boundaries of science and engineering to create cell-based products for commercial use and is pioneering a biotech revolution that promotes global wellbeing and sustainability. The Company’s technology platform, a patented and validated state-of-the-art 3D cell expansion system, advances novel cell-based solutions for a range of initiatives— from medicine and climate change to food scarcity, animal cruelty and beyond. Pluri’s method is uniquely accurate, scalable, cost-effective, and consistent from batch to batch. Pluri currently operates in the field of regenerative medicine and food-tech and aims to establish partnerships that leverage the company’s 3D cell-based technology to additional industries that require effective, mass cell production. To learn more, visit us at www.pluri-biotech.com or follow us on LinkedIn and Twitter.
|
Open
|
Cell Therapy, Biotechnology, and Regenerative Medicine
|
Open
|
MATAM Park, Bldg #5
|
Haifa
|
|
IL
|
31905
|
|
Pluristem Therapeutics
|
Health Care
|
Health Care Equipment & Services
|